menu
    • menu
    [{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Eisai | Xuanwu Hospital, Beijing","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Donepezil","moa":"Acetylcholinesterase","graph1":"Neurology","graph2":"Phase IV","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ Eisai | Xuanwu Hospital, Beijing","highestDevelopmentStatusID":"11","companyTruncated":"Beijing Friendship Hospital \/ Eisai | Xuanwu Hospital, Beijing"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Trendful Kangjian Medical Information Consulting Limited Company","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Integrin alpha-5","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Beijing Friendship Hospital \/ Beijing Trendful Kangjian Medical Information Consulting Limited Company","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Friendship Hospital \/ Beijing Trendful Kangjian Medical Information Consulting Limited Company"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tislelizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People\u2019s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Newish Technology Beijing","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous Tcm Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Friendship Hospital \/ Newish Technology Beijing","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ Newish Technology Beijing"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Nuwacell Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NCR300","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Beijing Friendship Hospital","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Chymotrypsin","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beijing Friendship Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Beijing Friendship Hospital \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Friendship Hospital \/ Beijing Friendship Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by Beijing Friendship Hospital

    Menu

    Beijing Friendship Hospital

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Chymotrypsin

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Healthgen Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric ...

                            Details : Recombinant Human Chymotrypsin is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastric Mucosal Lesion.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Recombinant Human Chymotrypsin

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Healthgen Biotechnology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Nuwacell Biotechnologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（...

                            Details : NCR300 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 04, 2024

                            Lead Product(s) : NCR300

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Nuwacell Biotechnologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer

                            Details : Tislelizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 18, 2022

                            Lead Product(s) : Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Beijing Hospital | Peking Union Medical College Hospital | Peking University First Hospital | Peking University People's Hospital | Peking University Cancer Hospital & Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

                            Details : Capecitabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 03, 2021

                            Lead Product(s) : Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : New Horizon Health | BeOne Medicines | Beijing Chao Yang Hospital | Xuanwu Hospital, Beijing | Tianjin Medical University General Hospital | People’s Hospital of Tianjin | Tianjin Medical University Cancer Institute and Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Recipient : CSPC Baike

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome

                            Details : Pegfilgrastim is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphohistiocytosis, Hemophagocytic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 05, 2020

                            Lead Product(s) : Pegfilgrastim

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Recipient : CSPC Baike

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Tcm Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Newish Technology Beijing

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)

                            Details : Autologous Tcm Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 14, 2018

                            Lead Product(s) : Autologous Tcm Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Newish Technology Beijing

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Eisai | Xuanwu Hospital, Beijing

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

                            Details : Donepezil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2016

                            Lead Product(s) : Donepezil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Eisai | Xuanwu Hospital, Beijing

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Beijing Friendship Hospital

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tauroursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Sponsor : Beijing Trendful Kangjian Medical Information Consulting Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cir...

                            Details : Tauroursodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Cirrhosis, Biliary.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 20, 2013

                            Lead Product(s) : Tauroursodeoxycholic Acid

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Sponsor : Beijing Trendful Kangjian Medical Information Consulting Limited Company

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth